Abstract:Hereditary angioedema due to C1 inhibitor deficiency (HAE-C1INH) is a rare congenital disorder that causes episodic swelling. Decreased or dysfunctional C1INH, the key inhibitor of the kinin-kallikrein system, leads to increased plasma kallikrein activity and the resultant excessive bradykinin causes angioedema(1).The morbidity and decreased quality of life of HAE-C1INH patients has motivated the increasing use of long-term prophylaxis (LTP) to prevent swelling attacks, when modern LTP agents became available a few years ago. The oral kallikrein antagonist berotralstat was approved in the United States and European Union in 2020 and 2021, respectively. The 2021 international HAE-C1INH guideline recommends berotralstat as a first-line therapy alongside plasma-derived C1 inhibitor (pd-C1INH) and lanadelumab(2).Herein, we present a practical guide to aid the clinician in the optimal use of berotralstat in HAE-C1INH based on available data and the experience at the Angioedema Centers of Reference and Excellence(3) in Berlin, Germany and Edmonton, Canada.Berotralstat is an oral small molecule that specifically inhibits plasma kallikrein. It is administered once daily at a dose of 150 mg. In the United States, a 110 mg dose is also available. It achieves a steady state plasma concentration in 6-12 days and has an elimination half-life of 93 hours(4). Administration with food does not impact the maximum serum concentration or total exposure of the medication(4).The efficacy of berotralstat was established in a double-blind, parallel-group study of 24 weeks duration(APEX-2). There were n=121 subjects randomized 1:1:1 to placebo, berotralstat 150 mg daily, or berotralstat 110 mg daily, and there was a 44% and 30% reduction in attack frequency/month in the treatment versus placebo arm at the 150 and 110 mg doses, respectively(5). The subsequent extension studies showed persistent and perhaps increased efficacy over time, with the 150 mg arm achieving a 79% reduction in attack frequency compared to baseline(6, 7) after 6 months (n=21). Real-world evidence studies have confirmed these results in various countries(8-10).Berotralstat was generally well tolerated at both doses. There was one severe adverse event (SAE)in the 110-mg berotralstat and three SAEs in the placebo arm, none of which were classified as drug related(5). The most frequent side effects observed in APEX-2 were gastrointestinal (GI) symptoms (e.g., abdominal discomfort, diarrhea). These were seen in 50% (20/40) of subjects receiving berotralstat 150 mg versus 36% (14/39) of subjects receiving placebo but tended to resolve over time. The GI symptoms can be mitigated by taking the medication with the largest meal of the day. Additionally, the graded introduction of berotralstat using the Berlin protocol, which involves starting with 1 tablet (150 mg) every third day and then increasing dosing frequency as tolerated to 1 tablet every other day and finally to 1 tablet daily, can improve tolerability (11). Some clinicians worry that GI upset may be misattributed to abdominal angioedema and result in inappropriate use of on-demand therapy. But, in our experience, patients (including those who have and have not had previous abdominal episodes) are generally able to differentiate between these when given anticipatory guidance. Before initiating therapy with berotralstat, patients must be informed about the possibility of gastrointestinal side effects, but care should be taken not to overemphasize this point in order to avoid nocebo effects. Additionally, headache was seen in 10.0% (4/40) of patients in the 150 mg arm of APEX-2 but also in 5.1% (2/39) of patients in the placebo arm. In our experience, it has not been a patient concern.QT interval prolongation was observed with berotralstat at doses 3-fold greater than that used clinically. At the approved dose of 150 mg daily berotralstat does not cause significant QT interval prolongation and electrocardiographic monitoring is not required. In APeX-2, one patient discontinued therapy due to elevated liver enzymes in the context of prior therapy with attenuated androgens. However, no regular laboratory monitoring is needed according to the drug monograph(4) and we have not observed elevated liver enzymes in our patients.Berotralstat is metabolized in the liver by CYP2D6 and CYP3A4 and hence may increase the plasma concentration of concomitant medications also metabolized by these enzymes (Table 1)(4). In some instances, reducing the dose of an interacting medication may be helpful. For example, one author has combined amlodipine with berotralstat and reduced the dose of the former (amlodipine 10 mg to 5 mg daily) without any loss of blood pressure control. Patients using a statin also metabolized by CYP3A4 (e.g., atorvastatin) can be switched to rosuvastatin, which is not a major CYP3A4 substrate (12) and thus does not interact with berotralstat. Given the poten -Abstract Truncated-

Sebetralstat for On-demand Treatment of Hereditary Angioedema Attacks: Results of the Double-blind, Placebo-controlled Phase 3 KONFIDENT Trial

A phase 2 open-label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema

CRISPR-Based Therapy for Hereditary Angioedema

Advent of oral medications for the treatment of hereditary angioedema

Berotralstat in hereditary angioedema due to C1 inhibitor deficiency: first real-world evidence from a Canadian center

Clinical Progress in Hepatic Targeting for Novel Prophylactic Therapies in Hereditary Angioedema

Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study

Patient-level indirect treatment comparison of lanadelumab versus pdC1-INH i.v. in hereditary angioedema patients: PATCH study

Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study

Risankizumab Versus Ustekinumab for Moderate-to-Severe Crohn’s Disease

Hereditary angioedema, emergency management of attacks by a call center

Clinical Experience with Berotralstat in Patients with Hereditary Angioedema with Normal C1-Esterase Inhibitor: A Commented Case Series

Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma

Kallikrein inhibitors for angioedema: the progress of preclinical and early phase studies

Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration

The Crimson 1 Study: A Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous Marzeptocog Alfa (activated) for on-Demand Treatment and Control of Bleeding Episodes in Subjects with Hemophilia A or Hemophilia B, with Inhibitors

Exploring disease-specific metabolite signatures in hereditary angioedema patients

MO230A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF ATRASENTAN IN PATIENTS WITH IGA NEPHROPATHY (THE ALIGN STUDY)

A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema

Safety of C1-esterase inhibitor in acute and prophylactic therapy of hereditary angioedema: findings from the ongoing international Berinert patient registry

Berotralstat for hereditary angioedema with C1 inhibitor deficiency: a practical guide for clinicians